219 related articles for article (PubMed ID: 22507895)
21. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
Ahmad Khan F; Gelmanova IY; Franke MF; Atwood S; Zemlyanaya NA; Unakova IA; Andreev YG; Berezina VI; Pavlova VE; Shin SS; Yedilbayev AB; Becerra MC; Keshavjee S
Clin Infect Dis; 2016 Jul; 63(2):214-20. PubMed ID: 27161772
[TBL] [Abstract][Full Text] [Related]
22. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study.
Keshavjee S; Gelmanova IY; Farmer PE; Mishustin SP; Strelis AK; Andreev YG; Pasechnikov AD; Atwood S; Mukherjee JS; Rich ML; Furin JJ; Nardell EA; Kim JY; Shin SS
Lancet; 2008 Oct; 372(9647):1403-9. PubMed ID: 18723218
[TBL] [Abstract][Full Text] [Related]
23. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
[TBL] [Abstract][Full Text] [Related]
24. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
[TBL] [Abstract][Full Text] [Related]
25. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh.
Rifat M; Hall J; Oldmeadow C; Husain A; Hinderaker SG; Milton AH
BMJ Open; 2015 Sep; 5(9):e008273. PubMed ID: 26351185
[TBL] [Abstract][Full Text] [Related]
26. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
[TBL] [Abstract][Full Text] [Related]
27. [THE FREQUENCIES AND MANAGEMENT OF ADVERSE REACTIONS IN MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT].
Sasaki Y; Yoshiyama T; Okumura M; Morimoto K; Miyamoto M; Irina ; Yoshimori K; Kurashima A; Ogata H; Gotoh H
Kekkaku; 2017 Jan; 92(1):11-19. PubMed ID: 30646468
[TBL] [Abstract][Full Text] [Related]
28. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
[TBL] [Abstract][Full Text] [Related]
30. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance.
Gelmanova IY; Keshavjee S; Golubchikova VT; Berezina VI; Strelis AK; Yanova GV; Atwood S; Murray M
Bull World Health Organ; 2007 Sep; 85(9):703-11. PubMed ID: 18026627
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
[TBL] [Abstract][Full Text] [Related]
32. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.
Podewils LJ; Gler MT; Quelapio MI; Chen MP
PLoS One; 2013; 8(7):e70064. PubMed ID: 23922904
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
[TBL] [Abstract][Full Text] [Related]
34. Patient Characteristics Associated with Tuberculosis Treatment Default: A Cohort Study in a High-Incidence Area of Lima, Peru.
Lackey B; Seas C; Van der Stuyft P; Otero L
PLoS One; 2015; 10(6):e0128541. PubMed ID: 26046766
[TBL] [Abstract][Full Text] [Related]
35. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
36. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
37. Psychological distress and its effect on tuberculosis treatment outcomes in Ethiopia.
Tola HH; Shojaeizadeh D; Garmaroudi G; Tol A; Yekaninejad MS; Ejeta LT; Kebede A; Karimi M; Kassa D
Glob Health Action; 2015; 8():29019. PubMed ID: 26610316
[TBL] [Abstract][Full Text] [Related]
38. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.
Langendam MW; Tiemersma EW; van der Werf MJ; Sandgren A
PLoS One; 2013; 8(1):e53599. PubMed ID: 23326464
[TBL] [Abstract][Full Text] [Related]
39. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
Kliiman K; Altraja A
Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
[TBL] [Abstract][Full Text] [Related]
40. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
